Press
Releases

Press Releases

June 29, 2021
Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteers Altimmune will discontinue further development of AdCOVID and focus its resources on its ongoing obesity and liver programs Altimmune also provides an update on its T-COVID™  Phase 1/2 Clinical Trial
 

Investor Contact

Will Brown
Chief Financial Officer

Email: wbrown@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe